Previous close | 130.12 |
Open | 131.72 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 128.98 - 130.92 |
52-week range | 99.14 - 133.10 |
Volume | |
Avg. volume | 8,287,572 |
Market cap | 327.318B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 143.58 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (2.38%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank […]
Merck & Co., Inc. ( NYSE:MRK ) just released its quarterly report and things are looking bullish. The company beat...
On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me